anti-CD19 CAR gamma delta T cells

**Anti-CD19 CAR gamma delta T cells** are genetically engineered T cells in which γδ T lymphocytes are modified to express a chimeric antigen receptor (CAR) specific for the CD19 antigen. CD19 is a cell surface molecule widely expressed on B cells and B cell malignancies. CAR γδ T cells combine the tumor recognition capabilities of the synthetic CAR targeting CD19 with the innate, MHC-independent targeting properties of γδ T cell receptors. This therapy aims to improve cancer immunotherapy by providing dual antigen recognition: both through engineered CAR and endogenous γδ TCR, increasing specificity and efficiency while reducing risks such as graft-versus-host disease. This approach is in clinical and preclinical development for various B cell-derived malignancies and some solid tumors[1][2][3]. CAR γδ T cells are capable of direct cytotoxicity against tumor cells through perforin/granzyme pathways, induction of apoptosis via FasL and TRAIL, effector cytokine release (IFN-γ, TNF-α), and improved tumor infiltration compared to conventional αβ CAR T cells. These cells can be generated by expanding γδ T cells ex vivo and transducing them with anti-CD19 CAR constructs, followed by infusion back into the patient[2].

Brand names

anti-CD19 CAR gamma delta T cellsanti-CD-19 CAR gamma delta T cellsanti-CD 19 CAR gamma delta T cells

Other names

CD19-targeted CAR γδ T cellsanti-CD19 CAR γδ T cells